Skip to main content
SpringerLink
Log in

Trastuzumab emtansine: lower AE-related costs in Canada

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 Canadian dollars

Reference

  • Piwko C, et al. Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. Clinical Drug Investigation : 28 Jun 2015. Available from: URL: http://doi.org/10.1007/s40261-015-0302-x

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trastuzumab emtansine: lower AE-related costs in Canada. PharmacoEcon Outcomes News 732, 31 (2015). https://doi.org/10.1007/s40274-015-2297-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2297-1

Search

Navigation